Abstracts A17 variability in CERs for same drugs for different indications, in some cases also varying by biomarkers. Primary care drugs had lower and less variable CERs than specialty drugs. Variations also exist in methodology used by different groups in modeling cost effectiveness, especially for time horizon and comparator. Majority of primary care drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate cost effectiveness. Among the top 10 drugs, quetiapine and erythropoietin had the highest variability across different studies, and atorvatstatin, salmetrol/fluticasone and clopidogrel had the most consistent ICER values across studies. CONCLUSIONS: This analysis shows the range, variability and methods used for calculation of ICER values for these high budget impact drugs and provides lessons for executives and policy makers. OBJECTIVES: To examine whether the move from the SF-36 to the SF-6D entails a loss in discriminative and evaluative strengths, the magnitude of that loss and whether it matters. METHODS: The study used relative validity (RV); a ratio of two F statistics, and standardized response means (SRM) to evaluate sensitivity and responsiveness of the SF-36 scales and SF-6D index. An RV of 1 reflected the most sensitive/ responsive scale and the smaller the RV the less sensitive the measure would be. Cohen's criterion for interpreting effect sizes was used to interpret the SRMs. The data used were initially collected for prior studies in seven diseases/conditions: chronic obstructive pulmonary disease, leg ulcers, the elderly in exercise, osteoarthritis, irritable bowel syndrome, migraine and obesity. Identified discriminative and evaluative variables were used to compare RVs and SRMs of the SF-36 scales and the SF-6D index. The mean RV differences and mean SRMs differences between the SF-36 scales and the SF-6D index represented the loss or gain in sensitivity. RESULTS: Data were available from a total of 10,089 subjects. No single SF-36 scale consistently had the largest RV or SRM, and there was no largest RV or SRM observed for the SF-6D index in any condition studied. Comparisons showed the SF-6D index was more discriminative with a mean RV difference of 0.09, (95% CI; 0.07 to 0.12) and more responsive with a mean SRM difference of 0.08, (95% CI; 0 to 0.16) than the SF-36 scales. However, based on longitudinal RVs the index was less responsive with a mean RV difference of 0.07, (95% CI; 0.01 to 0.15) than the SF-36 scales. CONCLUSIONS: Moving from the SF-36 to the SF-6D index entails a loss in evaluative strength and a gain in discriminative strength, a loss/gain too small to matter given the merits of either instrument.
PMC18 ELECTRONIC PRO VERSUS PAPER PRO: WHAT DO THE PATIENTS THINK?
Ross J, Marcovitz M Almac Clinical Technologies, Yardley, PA, USA OBJECTIVES: To examine patients' preferences and satisfaction on completing Patient Reported Outcome (PRO) assessments in studies that compared paper-administered to electronic versions. To identify which data collection method patients prefer. To explore aspects that makes the PRO experience more positive or negative for patients. METHODS: A large literature search was conducted to gather articles that utilized ePRO. From that, articles were identified and reviewed that compared paper to ePRO and assessed for patient satisfaction/preferences. RESULTS: 119 articles were identified that utilized ePRO; 26 (21.8%) compared paper to ePRO. Of the 26, 17 (65.4%) reported on patient satisfaction/preferences. Electronic modalities consisted of handheld devices (70.6%), interactive voice response system (IVRS) (phone) (17.6 %), electronic data capture system (5.9%) and both IVRS and handheld (5.9%). Patient satisfaction/preference was assessed through either interviews (41.2%) or questionnaires (58.8%). Patients reported preferring ePRO over paper in 88.2% of the articles. Positives aspects of paper included: familiarity, not dependent on technology that may malfunction and ease of reading. Negative aspects of paper included: forgetting to complete and burden. Positive aspects of ePRO included: liked the diary's appearance, convenient, ease of data entry, fast/efficient, saves trees, reminders, overall survey experience, more fun/novel, easier on eye, more up-to-date, and comfort in handling. Negative aspects of ePRO included: system problems/failures, difficulty to read, difficult to use, instructions could have been simpler, and inability to change reminder time or enter data late. CONCLUSIONS: As PRO are measures that come directly from the patients, it is important to identify their preferences and aspects of what makes their experiences more positive. These findings suggest that patients overall preferred ePRO and identified more positive aspects for ePRO. Both positive and negative aspects reported are equally valuable in identifying how PRO data collection can be improved to provide patients with the most positive experiences.
PMC19 DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE IN CHINA
Li M 1 , Bao Z 2 , Zhou J 2 , Luo N 3 1 China Pharmaceutical University, Nanjing, Jiangsu, China, 2 The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, 3 National University of Singapore, Singapore, Singapore OBJECTIVES: Health-related quality of life (HRQoL) instruments used in China are mainly from Western countries. Such instruments may not cover all the important health dimensions relevant to Chinese people as health is a culture-specific concept. However, there is a paucity of empirical data on what good health is to Chinese people. The objective of the current study is to identify health dimensions with which Chinese people use to define health. METHODS: A convenience sample of 200 adult Chinese (healthy persons: 80; inpatients: 120) were interviewed face to face. Open questions were used to elicit characteristics and life domains of good health. RESULTS: Fourteen health dimensions were identified. The 5 most frequently alluded dimensions were: mood (35.5%), absence of disease (33.3%), mobility (25.1%), ability to work (22.4%), and eating (17.5%). Other dimensions included vitality, pain or discomfort, physical fitness, sleep, freedom, self-care, social relationship, enjoyment, and cognition. More proportion of healthy persons than patients quoted mood and self-care as dimensions of health while more patients emphasized ability to work. Males regarded eating as a health dimension more often than females while females quoted self-care and social relationship more frequently than males. With regard to age, older persons valued ability to work more than younger people while more younger people thought absence of pain or discomfort is a characteristic of good health. CONCLUSIONS: This study provides useful information for assessing the adequacy of HRQoL instruments developed in Western countries for the Chinese population in China.
PMC20 THE TRANSLATION AND LINGUISTIC VALIDATION OF THE EQ-5D VISUAL ANALOGUE SCALE (VAS)
Clough LA, Ashcroft-Jones AJ, Furtado T, Wild D Oxford Outcomes Ltd, Oxford, Oxon, UK OBJECTIVES: The EQ-5D has been translated into many languages. The Euroqol group have recently altered and clarified the VAS scale. The objective of this study was to produce translations that are conceptually equivalent to the original and to other language versions, ensuring the relevance of the translations within the target cultures. METHODS: A standard methodology was employed: 1 forward and 1 back translation, review and developer review; or an in-country review and developer review; linguistic validation interviews with 8 subjects, a mix of healthy people and patients, a second developer review and 2 proofreadings. RESULTS: The translation process highlighted numerous cultural and linguistic issues, including: 1) Cognitive interviews showed that there was no clear Dutch word for scale, so an explanation likening the scale to a thermometer as in the previous 3L VAS was necessary; 2) In some cultures 'mark an X on the scale' was difficult to render, and had to be amended by using alternative verb formations and formatting; 3) Though the new VAS mentions only 'health', in some languages, it was necessary to use "health state" to avoid confusion, e.g. in Czech "health" alone means "good health."; 4) In some languages the concepts of "health" and "health state" had different temporal associations. In Korean, "health" referred to a longer period of time, so "health today" had to be expressed by "health state today"; 5) Russian patients understood "health state" as the evaluation given by a doctor or test results, therefore "in your opinion" was added. CONCLUSIONS: The EQ-5D VAS has been translated and linguistically validated using a rigorous translation process. A number of cultural and linguistic issues became apparent and were resolved. The measure is now appropriate for use in multinational trials.
PMC21

PATIENT-REPORTED OUTCOMES IN PRODUCT DEVELOPMENT GUIDANCE
Mordin M 1 , Lewis S 2 , Gnanasakthy A 3 , Demuro-Mercon C 2 , Copley-Merriman K 1 , Fehnel S 2 1 RTI Health Solutions, Ann Arbor, MI, USA, 2 RTI Health Solutions, Research Triangle Park, NC, USA, 3 Novartis Pharma, East Hanover, NJ, USA OBJECTIVES: Patient-reported outcomes (PRO) have received increasing attention from regulatory agencies regarding intended use of the data for promotional labeling claims. However, some disease areas and/or regulatory bodies necessitate the use of PRO data to substantiate product efficacy for securing approval. Therefore, the research objective was to determine how many of the final product development guidance available from EMEA and FDA for clinical/medical research indicate PRO as a mandatory component of efficacy. METHODS: Final guidance documents from the EMEA and FDA were reviewed for mention of PRO. EMEA Guidance documents that fell under the following categories were excluded: Clinical Pharmacology and Pharmacokinetics, Blood and Blood Forming Organs, Blood products (including biotech alternatives), and Herbals. Included in FDA Guidance review were those listed under the "Clinical/Medical" heading. The following data were abstracted from each guidance: guidance number, name, issue date, disease area, body system classification, PRO requirement, PRO endpoint hierarchy, and a summary of the PRO language included in the guidance. PRO statements were then characterized within each of the following categories (yes/no): signs/symptoms, function/feeling, HRQOL, or patient global rating. RESULTS: Of the 134 final guidance documents reviewed (EMEA = 81, FDA = 53), 52 mention PRO (EMEA n = 39; FDA n = 13). Within EMEA, PRO is
